AlphAIAlphAI — Financial news for AI agents
SEC EDGARAUG 251 min read$OMER

Borges David J. sold $207K of OMER

Borges David J. (VP, Finance & CAO) sold 10,906 shares of OMEROS CORP (OMER) at an average of $18.96 ($18.95–$19.10, $0.21M total) across 2 trades over 2026-08-21 to 2026-08-24 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Borges David J.
Published Aug 25, 2026, 9:40 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 25, 2026, 9:41 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$OMER
Neutral
high confidence
Mentioned
$OMER
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$OMERNeutralLow
01

Why it matters

The transaction is a routine insider divestiture with negligible market impact.

02

Market read

Limited relevance; primarily of interest to existing shareholders monitoring insider activity.

03

What to watch

Potential tax or liquidity motives for the sale; no operational insight.

Relevance 3/10Novelty 4/10Timing: post‑filing on 2026‑08‑25

Background

Form 4 filings disclose insider transactions; a 10b5‑1 plan indicates a pre‑arranged sale, often neutral.

Company-level read

Ticker impact

$OMERNeutralHigh confidence
Context

VP of Finance & CAO sold 10,906 shares for $206,805 via a 10b5‑1 plan, reducing his stake to zero.

Expected impact

No significant price impact expected.

Evidence & confidence

The sale size (~$0.2M) is small relative to market cap and was pre‑arranged, indicating no new negative information.

Market effects

Sector

None; insider sale does not affect sector trends.

Regional

None; limited to OMER shareholders.

Global

Minimal; isolated corporate filing.

Counterpoint

What could challenge this read

If the insider had a large unreported stake, the sale could signal concerns, but here the stake was fully liquidated via a plan.

Key entities

  • Officer
    Borges David J.

    Vice President, Finance & Chief Accounting Officer at OMEROS Corp.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

OMER insider trading history →

Related articles

OCT 19
$AZNMedAI 8/10

CHMP October decisions: AstraZeneca pulls prostate cancer filing; Orphelia gets a second chance; Ascendis nears EU launch

AstraZeneca withdrew its EU application for Truqap in prostate cancer. Orphelia Pharma gained CHMP backing for Kizfizo in glioblastoma. Ascendis Pharma neared EU approval for Yuviwel in achondroplasia. Sobi expanded Tryngolza's use to severe hypertriglyceridemia. Pfizer withdrew Ibrance's EU expansion. Revolution Medicines got CHMP backing for Rasonque in pancreatic cancer. Omeros failed to overturn Yartemlea's EU rejection. Lilly advanced Foundayo for obesity and diabetes in Europe.

european-biotechnology.com3 min
OCT 16
$OMERHighAI 8/10

Why is Omeros stock sliding today?

Omeros (OMER) stock fell 5.4% in pre-market trading after the European Medicines Agency's committee issued a second negative opinion on its Yartemlea drug application. The company will end its European compassionate-use program and abandon plans to license EU commercialization rights. Insiders sold $3M in shares over the past year. The stock traded at $17.77, down from $18.79. The U.S. launch of Yartemlea remains on track, with next earnings expected in mid-November.

investing.com2 min